Tag: science

UAE’S TII PROBE SET TO MAKE HISTORIC ASTEROID LANDING

by jezzabellemente, posted in Uncategorized

KUALA LUMPUR, Oct 5 (Bernama) — The Technology Innovation Institute (TII) has revealed the United Arab Emirates (UAE)-built probe for the Emirates Mission to the Asteroid Belt (EMA).

In a statement, TII said the probe will soon travel to Colorado, United States, for final integration with the MBR Explorer spacecraft ahead of its planned 2028 launch.

In a historic first, TII’s probe will image two planets and seven asteroids — flying past six asteroids in the main belt before culminating in a rendezvous with and landing on the seventh, 269 Justitia. If successful, the landing will make Justitia only the seventh asteroid in history to be reached on the surface by the probe.

“Our teams at TII have developed a system designed to withstand extreme conditions, operate with exceptional precision, and deliver meaningful science billions of kilometres from Earth.

“The mission reflects not only the calibre of our talent, but also the depth of scientific and engineering capability the UAE has built to contribute to some of the world’s most ambitious space missions,” said TII Chief Executive Officer, Dr Najwa Aaraj in a statement.

Designed, built and tested end-to-end in Abu Dhabi by TII’s Propulsion and Space Research Center, in collaboration with the UAE Space Agency, HEX20, Khalifa University and UAE University’s National Space Science and Technology Center, the TII-built probe is the mission’s only deployable payload.

It will separate from MBR Explorer to make contact with Justitia’s surface at the furthest point of the mission and operate fully autonomously in deep space, capturing close-range images and excavating the asteroid’s surface to provide new insights into its composition and physical characteristics.

The MBR Explorer spacecraft will travel approximately five billion kilometres over eight years, using gravity-assist manoeuvres at Venus, Earth and Mars, and conducting close encounters with six asteroids before arriving at 269 Justitia.

TII said the spacecraft is scheduled to launch from Japan in March 2028 within a narrow three-week launch window aligned to interplanetary conditions. On arrival, the MBR spacecraft will spend approximately seven months in orbit around Justitia, beginning at 250 kilometres and descending through a series of lower orbits.

The probe will deploy during a low-altitude pass in early 2036, then descend and make contact with the surface, imaging continuously and transmitting to the spacecraft above. The subsequent images will allow scientists to study material beneath the surface layer that cannot be characterised from orbit.

— BERNAMA

Dr. Falk Pharma and Renexxion announce positive results on naronapride in gastroparesis from the global phase 2b MOVE-IT trial

by jezzabellemente, posted in Uncategorized

  • MOVE-IT met the primary endpoint with statistically significant improvement in gastroparesis symptoms in 20 mg and 40 mg TID doses vs placebo
  • Improvements observed across key symptoms, including nausea, early satiety, post-prandial fullness and upper abdominal pain
  • Favorable safety and tolerability profiles
  • Late-breaking oral presentation delivered at Digestive Disease Week (DDW) 2026 in Chicago, IL

FREIBURG, Germany and ROSCREA, Ireland, May 5 (Bernama-GLOBE NEWSWIRE) — Dr. Falk Pharma GmbH (“Dr. Falk Pharma”), a research-based pharmaceutical company specializing in digestive and metabolic medicine, and Renexxion Ireland Limited (“Renexxion”), a clinical-stage biopharmaceutical company, today announced positive results from MOVE-IT (NCT05621811), a global Phase 2b, randomized placebo-controlled trial evaluating the efficacy, safety, and tolerability of naronapride in adults with gastroparesis. 

The double-blind, multicenter, 12-week study enrolled 328 adults with moderate-to-severe idiopathic or diabetic gastroparesis symptoms and objective evidence of delayed gastric emptying. Eligible patients received either 10 mg, 20 mg, 40 mg naronapride, or placebo, administered orally three times a day (TID) for 12 weeks.  

MOVE-IT met the primary endpoint, demonstrating statistically significant improvement versus placebo in the American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary (ANMS GCSI-DD) Core Symptom Score in the 20 mg TID (p=0.0046) and 40 mg TID (p=0.0156) groups. The ANMS GCSI-DD is a content-validated, patient-reported outcome instrument that assesses the five cardinal gastroparesis symptoms: nausea, vomiting, early satiety, postprandial fullness and upper abdominal pain.

Table 1. Primary endpoint – Change from baseline to Week 12 in the average weekly ANMS GCSI-DD Core Symptom Score

  Naronapride 
10 mg TID		Naronapride
20 mg TID		Naronapride
40 mg TID		Placebo
TID
Total PopulationN=83N=80N=80  N=85
Baseline (BSL)

Week 12		 Mean (SD)

Mean (SD)		 2.450 (0.388)

1.155 (0.797)		 2.429 (0.341)

0.883 (0.759)		 2.462 (0.450)

0.907 (0.780)		 2.402 (0.396)

1.280 (0.911)
Change to Week 12 LS Mean (SE)
 +/- 95% CI		  -1.244 (0.100)
 [-1.440, -1.048]		  -1.512 (0.102)
 [-1.712, -1.311]		 -1.452 (0.100)
 [-1.649, -1.256]		 -1.106 (0.095)
 [-1.293, -0.920]
Difference to
Placebo		 LS Mean (SE) -0.138 (0.136) -0.405 (0.137) -0.346 (0.136) 
Dunnett-Hsu
Adjusted		 97.5%-CI
 p-value†		 [-∞, 0.183]
 0.3112		 [-∞, -0.081]
 0.0046		 [-∞, -0.024]
 0.0156		 

CI = Confidence interval; LS Means = Least square means; N = Number of participants in analysis population; SD = Standard deviation; SE = Standard error. † One-sided

Naronapride also demonstrated statistically significant improvements versus placebo from baseline to Week 12 across key secondary and exploratory endpoints in the total population:

  • ANMS GCSI-DD Composite Score (core score excluding vomiting): Statistically significant improvements observed in 20 mg (p=0.0024) and 40 mg (p=0.0117) TID dose groups versus placebo.
  • Responder Analyses: Approximately 15-20% more participants achieved clinically meaningful improvement (defined as >1.0 decrease in ANMS GCSI-DD Composite Score) with naronapride 20 mg or 40 mg TID vs. placebo, with no added benefit of 40 mg over 20 mg.  
  • Patient-Reported Quality of Life (QoL): Global improvements reflecting meaningful benefit beyond core symptom reduction and supporting consistency of treatment effect across validated symptom assessment instruments.
  • Improvement in gastric emptying breath test (GEBT): All active doses achieved greater gastric emptying versus placebo. Maximum improvement with 20 mg (mean -21.95 minutes) and 40 mg (mean –14.92 minutes) versus placebo (mean –10.96 minutes).

Consistent with previous studies, the safety and tolerability profiles were favorable, with no new safety signals identified versus placebo, including cardiac, neuropsychiatric, or prolactin-related signals. To date, naronapride has been studied in over 1200 subjects, with a safety profile reflecting its minimal systemic absorption. 

Dr. Kai Pinkernell, M.D., Managing Director Science & Innovation at Dr. Falk Pharma, commented: “We are excited about the outcomes showing a significant and clinically meaningful impact on gastroparesis symptoms, all combined with a favorable safety profile. This is an important step towards providing physicians and patients with a treatment option where few effective choices exist. We look forward to sharing these results with the scientific community, engaging with regulatory authorities, and moving decisively toward registration studies later this year and eventual commercialization.” 

Dr. Peter Milner, M.D., FACC, Chairman and CEO of Renexxion, commented: “These Phase 2b results represent a significant milestone for the naronapride program, demonstrating statistically significant improvement in gastroparesis symptoms with a favorable safety and tolerability profile. We believe naronapride’s locally acting, dual mechanism pharmacology and safety-by-design profile position it as a potential best-in-class therapy for gastroparesis, a disease with significant unmet medical need and limited, safe, effective long-term treatment options. Together with our partner Dr. Falk Pharma, we are now focused on advancing naronapride into late-stage development with the goal of bringing an important new treatment option to physicians and patients.”

About Naronapride
Naronapride is a potential best-in-class oral, locally acting pan-GI prokinetic designed to enhance coordinated motility across the digestive tract. Naronapride works through a differentiated dual mechanism of action- 5-HT4 receptor agonism and dopamine D2 receptor antagonism- modulating two validated targets on the luminal surface of the intestinal wall that regulate GI motility and nausea signaling.  Naronapride’s dual pharmacology, minimal systemic bioavailability, and differentiated pharmaceutical and pharmacokinetic profile are designed to deliver targeted activity within the GI tract while limiting systemic exposure. To date, naronapride has demonstrated a favorable safety and tolerability profile across nine Phase 1 clinical trials and five Phase 2 clinical trials conducted in multiple indications including gastroesophageal reflux disease, erosive esophagitis and chronic idiopathic constipation.

About Gastroparesis
Gastroparesis is a chronic gastrointestinal disorder characterized by delayed gastric emptying and debilitating symptoms including nausea, vomiting, early satiety, upper abdominal pain and postprandial fullness. Approximately 22 per 100,000 individuals across US and Europe are formally diagnosed with gastroparesis, while up to 12-times more experience symptoms consistent with the disease. Despite the substantial disease burden, the availability of safe and effective long‑term treatment options remains limited.

About Renexxion
Renexxion Ireland Limited, a wholly-owned Irish subsidiary of California-based Renexxion, Inc., is a privately held biopharmaceutical company committed to developing new therapies for patients with gastrointestinal disorders. Renexxion’s lead program is naronapride, a late-stage drug candidate being developed for multiple unmet indications in the upper and lower GI tract.

Further information on Renexxion can be found online: https://www.rnexltd.ie

Media Inquiries:   
Press@rnexltd.ie
+353 61 539121

About Dr. Falk Pharma GmbH  
Dr. Falk Pharma GmbH has been developing and marketing innovative medicines to treat a wide range of gastrointestinal disorders like inflammatory bowel disease or eosinophilic esophagitis as well as hepatobiliary disorders such as primary biliary cholangitis for over 60 years. As the international experts in digestive and metabolic medicine, the company brings together physicians, scientists, and patients to devise new and powerful approaches to patient care. Dr. Falk Pharma engages in pre-clinical and clinical stage research that aims to meaningfully improve therapeutic practice as well as patient health and well-being. A family-owned business with a global presence, Dr. Falk Pharma has ten affiliates in Europe and Australia and is continuously growing. The company has its headquarters and R&D facilities in Freiburg, Germany, its pharmaceutical products are manufactured in Europe, mainly at sites in Germany, France, Italy, and Switzerland. Falk employs approximately 1,550 individuals globally and 450 in Freiburg.

Further information on Dr. Falk Pharma can be found online: https://drfalkpharma.com

SOURCE: Dr. Falk Pharma

EarthDaily Achieves CEOS Analysis Ready Data (CEOS-ARD) Compliance

by jezzabellemente, posted in Uncategorized

Validation Confirms Science-Grade Integrity of the EarthDaily Constellation 

VANCOUVER, British Columbia and NEW YORK, March 13 (Bernama-GLOBE NEWSWIRE) — EarthDaily today announced that its data products have achieved CEOS Analysis Ready Data (CEOS-ARD) compliance, a globally recognized standard established by the Committee on Earth Observation Satellites (CEOS).

CEOS-ARD compliance confirms that EarthDaily data meet rigorous international requirements for radiometric calibration and geometric correction approaches, metadata completeness, and interoperability across time and datasets, enabling immediate quantitative analysis with minimal additional user processing.

Importantly, EarthDaily achieved CEOS-ARD compliance prior to full commercial availability of its complete constellation, a rare milestone for a commercial Earth observation system.

“This achievement validates the scientific foundation of our data,” said Don Osborne, Chief Executive Officer of EarthDaily. “We built the EarthDaily Constellation as a measurement system first. Daily coverage only matters if the data are stable, comparable, and trustworthy over time. CEOS-ARD compliance confirms we are delivering science-grade data at commercial scale.”

CEOS Analysis Ready Data standards are important to science mission interoperability and include a range of public government missions, including Sentinel and Landsat products. The framework was developed to address a persistent challenge in Earth observation: as global data volumes grow, users often lack the infrastructure and expertise required to process raw imagery for scientific and operational applications. Systematic provision of CEOS-ARD reduces that burden and supports more effective decision-making.

EarthDaily’s architecture was intentionally designed to ensure continuity with established scientific archives. Its radiometric calibration approach, spectral configuration, and geometric correction standards enable comparability and compatibility with Landsat and Sentinel data records. This design allows users to integrate EarthDaily data seamlessly into existing time-series analyses while benefiting from enhanced spectral diversity and daily revisit.

Compliance signals that EarthDaily delivers:

  • Science-grade radiometric and geometric correction
  • Interoperable datasets structured for robust time-series analysis
  • Immediate usability for advanced analytics and AI workflows
  • Reduced preprocessing burden and improved analytical reliability

The EarthDaily constellation was engineered around measurement integrity from inception. As highlighted in recent SpaceNews coverage examining the system’s development and on-orbit performance, the EarthDaily Constellation incorporates:

  • Rigorous radiometric calibration
  • Thermal characterization for spectral stability
  • Simultaneous collection across 22 spectral bands
  • Consistent local acquisition timing
  • Architecture aligned for interoperability with Landsat and Sentinel archives

These design principles ensure that EarthDaily data is globally consistent and scientifically reliable for long-term change detection.

With six additional satellites launching in May and continued expansion later this year, the EarthDaily Constellation will enter commercial operations in Summer 2026, delivering daily, consistent global coverage supported by CEOS-ARD compliant science-grade data.

This milestone reinforces EarthDaily’s position as a commercial provider bridging scientific rigor with scalable, AI-ready Earth observation infrastructure.

About EarthDaily

EarthDaily is a global Earth observation company focused on delivering science-grade data and analytics designed for broad-area change detection and decision-centric intelligence. With the upcoming launch of the EarthDaily Constellation, the company is building a foundation for daily, globally consistent Earth intelligence to support governments and enterprises operating in complex, high-impact environments.

To learn more, visit earthdaily.com and follow EarthDaily on LinkedIn (@EarthDaily) and X (@EarthDailyA).

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a00964c1-54f3-418d-800e-2c09394a2aa3


Contacts
Tanya Cross
Vice President, Global Marketing and Communications
EarthDaily
tanya.cross@earthdaily.com

Alliance Advisors IR
EarthDailyPR@allianceadvisors.com 

SOURCE: EarthDaily Analytics

Eyexora Establishes Co-Headquarters in Singapore to Accelerate Growth Across Asia-Pacific

by jezzabellemente, posted in Uncategorized

SINGAPORE, Nov 6 (Bernama-BUSINESS WIRE) — Eyexora, a biotech company pioneering innovative therapies for ophthalmic diseases through a hub-and-spoke model, today announced the establishment of its co-headquarters in Singapore, marking a major milestone in the company’s global expansion and deepening its commitment to advancing eye health worldwide. Eyexora’s seed financing was led by ClavystBio, a global life sciences investor based in Singapore, and its initial programs have been in-licensed from the Singapore Eye Research Institute (SERI).

The new Singapore headquarters will serve as a gateway to Eyexora’s growing activities across the Asia-Pacific region, supporting clinical development, research collaborations, and regional partnerships. This expansion further strengthens Eyexora’s collaboration with the Singapore Eye Research Institute (SERI), a long-standing partner in ophthalmic innovation.

Eyexora’s Singapore operations will be instrumental in driving the company’s mission to develop transformative, accessible treatments for patients with vision-threatening diseases, while advancing scientific collaboration in one of the world’s most dynamic healthcare innovation hubs.

“Singapore has become a global center for ophthalmic research and innovation, and we are proud to deepen our presence here,” said Theresa Heah, M.D., M.B.A., Chief Executive Officer and Vice Chair of the Board, Eyexora. “This new co-headquarters positions Eyexora at the heart of Asia-Pacific’s biomedical ecosystem and strengthens our collaboration with SERI. Together, we are accelerating the development of breakthrough therapies that can improve vision and quality of life for patients around the world.”

“This milestone reflects our vision to build a truly global ophthalmic company,” said William J. Link, Ph.D, Chairman of the Board at Eyexora. “Singapore’s strong research infrastructure and commitment to innovation make it an ideal base for expanding Eyexora’s partnerships and advancing the next generation of eye care solutions.”

“Eyexora’s new co-headquarters are a testament to Singapore’s leadership in ophthalmology research and clinical delivery, and position as a global life sciences hub,” said Khoo Shih, Ph.D, CEO, ClavystBio. “At ClavystBio, we are excited to partner seasoned leaders like Theresa, William and their team to accelerate meaningful innovations and make global health impact.”

Last month Eyexora announced the launch of its second spoke company, Y.ora Vision, Inc., focused on developing next-generation ophthalmic medical devices for glaucoma. The company’s creation, complementing initial spoke company, Serenora Therapeutics, Inc., underscores Eyexora’s commitment to building a global ecosystem of specialized ventures that advance innovation across key therapeutic areas in ophthalmology.

Eyexora’s Singapore co-headquarters complements its U.S. base in New York, and will anchor the company’s Asia-Pacific operations, including clinical, scientific, and strategic functions, as it continues to grow its global footprint.

About Eyexora

Eyexora is a global ophthalmology company pioneering a hub-and-spoke model to accelerate innovation in eye care. By centralizing scientific, clinical, regulatory, and commercial expertise, Eyexora advances a diversified pipeline of therapies and devices through focused subsidiaries, to reduce risk, improve efficiency, and scale impact. Founded by leaders with decades of ophthalmology experience and a track record of more than 30 successful company and product launches, Eyexora partners with clinician-scientists and research institutes worldwide to bring transformative eye care solutions to patients faster and smarter. For more information, visit www.eyexora.com.

About ClavystBio

ClavystBio is a life sciences investor and venture builder established by Temasek to accelerate the commercialization of breakthrough ideas into health impact. We invest and partner with founders and entrepreneurs to launch and grow global companies from Asia. Our focus spans therapeutics, digital health and medtech, with an emphasis on first-in-class science and technology. Our collaborative space, Node 1, provides plug-and-play spaces for ventures that have graduated from incubators to progress to their next milestones. By bringing startups together, we foster a vibrant and supportive community. For more information, please visit https://www.clavystbio.com/ and follow us on LinkedIn.

About Singapore Eye Research Institute (SERI)

Established in 1997, SERI is Singapore’s national research institute for ophthalmic and vision research. SERI’s mission is to conduct high-impact eye research that prevents blindness, low vision, and major eye diseases common to Singaporeans and Asians. Over the last decade, SERI has conducted landmark research projects that have led to tangible outcomes, patient benefits, and success stories. It has paved the way for significant improvements in how eye diseases are treated and prevented, not just for Singaporeans or Asians, but on a global scale.

At its inception, SERI saw a national remit in ophthalmic and vision research, and till today, SERI ensures that its facilities and resources are open to researchers across Singapore so that the greatest benefit may be obtained from what is a relatively small clinical ophthalmology catchment area in Singapore.

SERI has grown from a founding team of five in 1997 to a faculty of more than 253 staff, encompassing clinician scientists, scientists, research fellows, PhD students and support staff. This makes SERI one of the largest research institutes in Singapore, as well as the largest eye research institute in the Asia Pacific region. SERI has also over 255 adjunct faculties from various eye departments, biomedical institutes, and tertiary centres in Singapore. SERI has published an impressive array of 5,942 scientific papers and has secured external peer-reviewed competitive grants worth more than $473 million. As of December 2024, SERI’s faculty has been awarded with more than 1,425 national and international prizes and filed 188 patents.

As the research institute of the SNEC, and directly affiliated to the Yong Loo Lin School of Medicine, National University of Singapore, as well as the Duke-NUS Medical School, SERI undertakes vision research in collaboration with local clinical ophthalmic centres and biomedical research institutions, as well as major eye centres and research institutes throughout the world.

SERI ranks first globally in terms of eye publications per capita, far ahead of the US, UK, and Japan. With its impressive publication track record, SERI is comparable to renowned eye institutes, both regionally and internationally. Please see www.seri.com.sg.

View source version on businesswire.com: 
https://www.businesswire.com/news/home/20251104717799/en/

Contact

Media Contact
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com

Source : Eyexora

Spring Bio Solution Launches NCE Grid to decode Para IV Filing and First-to-File Opportunities

by jezzabellemente, posted in Uncategorized

SOMERSET, N.J., June 12 (Bernama-GLOBE NEWSWIRE) — Spring Bio Solution, a global leader in the comparator sourcing and clinical trial supplies, has launched NCE Grid, the world’s first free NCE-1 intelligence platform – built to decode, centralize, and visualize Para IV and NCE-1 opportunities in real-time.

Until now, tracking NCE exclusivity expirations and Paragraph IV filings has been a fragmented, manual, and cumbersome process, lacking a centralized solution. Regulatory updates are scattered across various portals, intelligence is buried in siloed databases, and timelines are tracked using spreadsheets. The result? Competitive blind spots, misaligned R&D, and a race already lost before it begins.

For generic pharmaceutical companies aiming to be the “first to file,” intelligence gaps, scattered data, and missed timelines can result in lost exclusivity and millions in revenue.

NCE Grid changes that.

NCE Grid is the world’s first free tool to integrate every critical data point, including molecule, innovator name, NCE-1 date, revenue, therapeutic usage, expected sales growth, and CAGR% into one intuitive platform. With real-time visualizations and actionable insights, NCE Grid empowers strategy, regulatory, and portfolio teams to identify, prioritize, and act on first-to-file opportunities with clarity and speed.

“We created NCE Grid because we saw too many companies struggle with fragmented insights and missed opportunities,” said Salim Shaikh, Founder and CEO of Spring Bio Solution. “In a race where timing is everything, our platform brings clarity, speed, and a competitive edge to decision-makers. When you think Para IV, think NCE Grid — Your trusted guide for strategic drug development.” 

To learn more, visithttps://ncegrid.springbiosolution.com/

About Spring Bio Solution

Spring Bio Solution partners with CROs, pharmaceutical companies, and research institutions worldwide, offering reliable solutions for comparator sourcing and clinical trial supplies. With offices and WDL (wholesale Drug Distribution License) facilities across the USA, EU, Singapore, and India, and a robust network of 400+ distribution partners and 30+ innovators, Spring Bio Solution ensures timely and compliant access to critical drug supplies.

Trusted by over 600 clients and maintaining a 99.9% success rate for sourcing comparator drugs/ RLDs/ innovator samples, the company offers industry-leading cold chain capabilities, ranging from -60°C to ambient temperatures. Through its partnership with LSPedia, Spring Bio Solution also ensures full DSCSA compliance and end-to-end traceability.

With experience supporting over 1,000 clinical trials and more than 12,000 bioequivalence studies, Spring Bio Solution empowers sponsors to de-risk operations and accelerate drug development with confidence.

For media inquiries, please contact:

Navdeep Trivedi
Vice President & Head, Digital Marketing
Spring Bio Solution
navdeep.trivedi@springbiosolution.com

SOURCE: Spring Bio Solution PTE.LTD